» Articles » PMID: 34422649

A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Aug 23
PMID 34422649
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.

Methods: We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.

Results: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.

Conclusions: In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.

Citing Articles

Advances in primary large B-cell lymphoma of immune-privileged sites.

Wang L, Guo M, Hou S Front Immunol. 2025; 16:1533444.

PMID: 40078990 PMC: 11896999. DOI: 10.3389/fimmu.2025.1533444.


A Nomogram for Predicting Overall Survival in Primary Central Nervous System Lymphoma: A Retrospective Study.

Ling Y, Miao X, Zhou X, Ma J, Lin Z, Li Q J Inflamm Res. 2025; 18:2091-2103.

PMID: 39959640 PMC: 11827503. DOI: 10.2147/JIR.S498121.


Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator.

Matsuda R, Maeoka R, Morimoto T, Nakazawa T, Morisaki Y, Yokoyama S J Neurooncol. 2024; 168(3):487-494.

PMID: 38658464 DOI: 10.1007/s11060-024-04692-5.


C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients.

Zuo J, Lei T, Zhong S, Zhou J, Liu R, Wu C Neurosurg Rev. 2023; 47(1):17.

PMID: 38112846 PMC: 10730673. DOI: 10.1007/s10143-023-02248-1.


Radiomic features define risk and are linked to DNA methylation attributes in primary CNS lymphoma.

Nenning K, Gesperger J, Furtner J, Nemc A, Roetzer-Pejrimovsky T, Choi S Neurooncol Adv. 2023; 5(1):vdad136.

PMID: 38024240 PMC: 10676053. DOI: 10.1093/noajnl/vdad136.


References
1.
Corry J, Smith J, Wirth A, Quong G, Liew K . Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998; 41(3):615-20. DOI: 10.1016/s0360-3016(97)00571-3. View

2.
Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

3.
Hayabuchi N, Shibamoto Y, Onizuka Y . Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys. 2000; 44(2):265-72. DOI: 10.1016/s0360-3016(98)00564-1. View

4.
Liu C, Lin S, Yang C, Yeh C, Kuan A, Wang H . A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med. 2020; 9(6):2134-2145. PMC: 7064125. DOI: 10.1002/cam4.2872. View

5.
Jang J, Kim Y, Kim S, Cho H, Chung H, Lee J . A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer. 2016; 57:127-35. DOI: 10.1016/j.ejca.2016.01.016. View